Fri, March 1, 2024

Keay Nakae Reiterated (ABUS) at Strong Buy and Held Target at $4 on, Mar 1st, 2024

Keay Nakae of Chardan Capital, Reiterated "Arbutus Biopharma Corporation" (ABUS) at Strong Buy and Held Target at $4 on, Mar 1st, 2024.

Keay, nor any peers, have made any analyst calls on ABUS in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30